Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
10.75
-0.65 (-5.70%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.55 - 11.25
52 week 8.05 - 28.60
Open 11.10
Vol / Avg. 1.21M/678,610.00
Mkt cap 587.40M
P/E     -
Div/yield     -
EPS -5.42
Shares 57.95M
Beta 3.89
Inst. own 94%
Mar 12, 2018
Q4 2017 Coherus BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 8, 2018
Coherus BioSciences Inc at JPMorgan Healthcare Conference - Webcast
Dec 14, 2017
Coherus BioSciences Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 7, 2017
Coherus BioSciences Inc at Credit Suisse Healthcare Conference - Webcast
Nov 6, 2017
Q3 2017 Coherus BioSciences Inc Earnings Call - Webcast
Nov 6, 2017
Q3 2017 Coherus BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -67.22%
Operating margin - -60.98%
EBITD margin - -59.40%
Return on average assets -130.73% -65.39%
Return on average equity -535.70% -1778.45%
Employees 127 -
CDP Score - -

Address

333 Twin Dolphin Dr Ste 600
REDWOOD CITY, CA 94065-1442
United States - Map
+1-650-6493530 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Officers and directors

Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 55
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 69
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 69
Bio & Compensation  - Reuters
Mats Wahlstrom Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Christos Richards Director
Age: 59
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 60
Bio & Compensation  - Reuters
James I. Healy M.D. Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr. Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters